SCHEMBL3344136

SCHEMBL3344136

CCOC(=O)c1cnc(-c2cc(F)cc(F)c2)cc1Cl

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
BAZ2B Q9UIF8 1/20 0.46
BAZ2A Q9UIF9 1/20 0.46
ALDH1A1 P00352 5/20 0.45
MEN1 O00255 1/20 0.45
KMT2A Q03164 1/20 0.45
JMJD6 Q6NYC1 1/20 0.44
DYRK1A Q13627 5/20 0.43
SMN1; SMN2 Q16637 3/20 0.43
NPC1 O15118 2/20 0.43
RAB9A P51151 2/20 0.43
TSHR P16473 1/20 0.43
MAPT P10636 2/20 0.42
LMNA P02545 1/20 0.42
MAPK1 P28482 1/20 0.42
ATM Q13315 1/20 0.42
CSNK1D P48730 1/20 0.42
HPGD P15428 2/20 0.42
GAA P10253 1/20 0.42
TDP1 Q9NUW8 1/20 0.42
JAK2 O60674 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3341192 0.88 ALDH1A1 (0.54) BAZ2BBAZ2AALDH1A1MEN1KMT2A
SCHEMBL3341133 0.88 JAK2 (0.53) ALDH1A1MEN1KMT2AJMJD6SMN1; SMN2
SCHEMBL3343855 0.82 MAPT (0.44) ALDH1A1MEN1KMT2ASMN1; SMN2NPC1
SCHEMBL3341652 0.80 JAK2 (0.55) ALDH1A1MEN1KMT2ASMN1; SMN2NPC1
SCHEMBL8219490 0.79 MAPT (0.43) ALDH1A1MEN1KMT2AJMJD6DYRK1A
SCHEMBL3343610 0.79 CYP1A2 (0.43) ALDH1A1SMN1; SMN2MAPTLMNAHPGD
SCHEMBL31318761 0.77 BAZ2B (0.45) BAZ2BBAZ2AALDH1A1MEN1KMT2A
SCHEMBL3652621 0.77 BAZ2B (0.51) BAZ2BBAZ2AALDH1A1MEN1KMT2A
SCHEMBL190973 0.77 BAZ2B (0.51) BAZ2BBAZ2AALDH1A1MEN1KMT2A
SCHEMBL29574609 0.77 BAZ2B (0.51) BAZ2BBAZ2AALDH1A1MEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20100160386-A1 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT 2010-06-24 US disclosed
US-20100160386-A1 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT 2010-06-24 US disclosed
US-20100160386-A1 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT 2010-06-24 US disclosed
WO-2008031500-A1 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) 2008-03-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100160386-A1 4-PHENOXY-NICOTINE ACID DERIVATIVES AND USE THEREOF AS PPAR-MODULATORS PPARA, PPARD, PPARG BAZ2B 818/4885BAZ2A 921/4885ALDH1A1 2083/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.